Alzamend Neuro Inc (ALZN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 04/30
(Values in U.S. thousands)
| 04-2025 | 04-2024 | 04-2023 | 04-2022 | 04-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,949 | 376 | 5,141 | 14,064 | 1,929 |
| TOTAL | $4,177 | $455 | $5,836 | $14,414 | $2,913 |
| Non-Current Assets | |||||
| PPE Net | 426 | 176 | 80 | 103 | N/A |
| TOTAL | $426 | $176 | $80 | $103 | $N/A |
| Total Assets | $4,603 | $632 | $5,916 | $14,516 | $2,913 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | N/A | N/A | N/A | 335 |
| Accounts payable and accrued liabilities | 635 | 2,925 | 2,870 | 1,165 | 564 |
| TOTAL | $635 | $3,226 | $2,870 | $1,165 | $900 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $635 | $3,226 | $2,870 | $1,165 | $900 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 2,896 | 93 | 72 | 71 | N/A |
| Common Shares | 0 | 0 | 0 | 10 | 7 |
| Retained earnings | -58,535 | -54,020 | -44,073 | -29,195 | -16,832 |
| Other shareholders' equity | 0 | 0 | -14,883 | -14,883 | -14,883 |
| TOTAL | $3,968 | $-2,594 | $3,046 | $13,352 | $2,013 |
| Total Liabilities And Equity | $4,603 | $632 | $5,916 | $14,516 | $2,913 |